Urology
Volume 54, Issue 6 , Pages 1120-1125 , December 1999

Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins

  • Tara Nickerson

      Affiliations

    • Department of Medicine, McGill University, Montreal, Quebec, Canada
    • ,
  • Michael Pollak

      Affiliations

    • Department of Medicine, McGill University, Montreal, Quebec, Canada
    • Department of Oncology, McGill University, Montreal, Quebec, Canada
    • Lady Davis Institute of the Jewish General Hospital, Montreal, Quebec, Canada
    • Corresponding Author InformationReprint requests: Michael Pollak, M.D., Lady Davis Institute, 3755 Côte Ste. Catherine Road, Montreal, Quebec H3T 1E2, Canada

Received 15 April 1999 ,Revised 28 June 1999 ,Accepted 28 June 1999.

References 

  1. Lopez-Otin C, Diamandis P. Breast and prostate cancer (an analysis of common epidemiology, genetic, and biochemical features). Endocrine Rev. 1998;19:365–396
  2. Simard J, Singh SM, Labrie F. Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex and nilutamide on androgen sensitive parameters. Urology. 1997;49:580–586
  3. Labrie F, Belanger A, Dupont A, et al.  Science behind total androgen blockade (from gene to combination therapy). Clin Invest Med. 1993;16:475–492
  4. Furr BJA, Valaccia B, Curry B, et al.  ICI 176,334 (a novel nonsteroidal peripherally selective antiandrogen). J Endocrinol. 1987;113:R7–R9
  5. Schellhammer PF, Sharifi R, Block NL, et al.  Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma (final report of a double-blind, randomized, multicenter trial). Urology. 1997;50:330–336
  6. Furr BJA. Relative potencies of flutamide and “Casodex.”. Endocrine-Related Cancer. 1997;4:197–202
  7. Iversen P, Tyrrell CJ, Kaisary AV, et al.  Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer (results from two multicenter randomized trials at a median follow-up of 4 years). Urology. 1998;51:389–396
  8. Kolvenbag GJCM, Blackledge GRP, Gotting-Smith K. Bicalutamide (Casodex) in the treatment of prostate cancer (history of clinical development). Prostate. 1998;34:61–72
  9. Blackledge GR. Clinical progress with a new antiandrogen, Casodex (bicalutamide). Eur Urol. 1996;29(suppl 2):96–104
  10. Tyrrell CJ, Kaisary AV, Iversen P, et al.  A randomised comparison of “Casodex” (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998;33:447–456
  11. Joyce R, Fenton MA, Rode P, et al.  High dose bicalutamide for androgen independent prostate cancer (effect of prior hormonal therapy). J Urol. 1998;159:149–153
  12. Steiner MS. Review of peptide growth factors in benign prostatic hyperplasia and urological malignancy. J Urol. 1995;153:1085–1096
  13. Peehl DM, Cohen P, Rosenfeld RG. Role of insulin-like growth factors in prostate biology. J Androl. 1996;17:2–4
  14. Chan JM, Stampfer MK, Giovannucci E, et al.  Plasma insulin-like growth factor-I and prostate cancer risk (a prospective study). Science. 1998;279:563–566
  15. Baserga R. The insulin-like growth factor I receptor (a key to tumor growth?). Cancer Res. 1995;55:249–252
  16. Kim HS, Nagalla SR, Oh Y, et al.  Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs) (characterization of connective tissue growth factor as a member of the IGFBP superfamily). Proc Natl Acad Sci USA. 1997;94:12981–12986
  17. Cohen P, Peehl DM, Lamson G, et al.  Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab. 1991;73:401–407
  18. Cohen P, Peehl DM, Stamey TA, et al.  Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab. 1993;76:1031–1035
  19. Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev. 1997;8:45–62
  20. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem. 1997;272:12181–12188
  21. Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun. 1997;237:690–693
  22. Nickerson T, Pollak M, Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2, 3, 4, and 5. Endocrinology. 1998;139:807–810
  23. Wong P, Pineault J, Lakins J, et al.  Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis. J Biol Chem. 1993;268:5021–5031
  24. Shimasaki S, Ling N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog Growth Factor Res. 1991;3:243–266
  25. English HF, Drago JR, Isaacs JT. Response of glandular versus basal rat ventral prostate epithelial cells to androgen withdrawal. Prostate. 1987;11:229–242
  26. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate. 1984;5:547–557
  27. Cockshott ID, Plummer GF, Cooper KJ, et al.  The pharmacokinetics of Casodex in laboratory animals. Xenobiotica. 1991;21:1347–1355
  28. Tonner E, Quarrie L, Travers M, et al.  Does an IGF-binding protein (IGFBP) present in involuting rat mammary gland regulate apoptosis?. Prog Growth Factor Res. 1995;6:409–414
  29. Guenette RS, Tenniswood M. The role of growth factors in the supression of active cell death in the prostate (an hypothesis). Biochem Cell Biol. 1994;72:553–559
  30. Huynh H, Seyam RM, Brock GB. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res. 1998;58:215–218
  31. Wilding G. Endocrine control of prostate cancer. Cancer Surv. 1995;23:43–62
  32. Tennant MK, Thrasher JB, Twomey PA, et al.  Insulin-like growth factor binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia and adenocarcinoma of the prostate. J Clin Endocrinol Metab. 1996;81:411–420
  33. Tennant MK, Thrasher JB, Twomey PA, et al.  Insulin-like growth factor binding proteins (IGFBP) -4, -5, and -6 in the benign and malignant human prostate (IGFBP-5 mRNA localization differs from IGFBP-5 protein localization). J Clin Endocrinol Metab. 1996;81:3783–3792
  34. Thomas LN, Cohen P, Douglas RC, et al.  Insulin-like growth factor binding protein 5 is associated with involution of the ventral prostate in castrated and finasteride-treated rats. Prostate. 1998;35:273–278
  35. Oh Y, Muller HL, Lamson G, et al.  Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. J Biol Chem. 1993;268:14964–14971
  36. Oh Y, Muller HL, Pham H, et al.  Insulin-like growth factor binding protein (IGFBP)-3 levels in conditioned media of Hs578T human breast cancer cells are post-transcriptionally regulated. Growth Reg. 1993;3:84–87

☆ This study was supported in part by a grant from the National Cancer Institute of Canada to Michael Pollak

PII: S0090-4295(99)00421-5

Urology
Volume 54, Issue 6 , Pages 1120-1125 , December 1999

Article Tools

* Image Usage & Resolution